G protein-coupled receptors (GPCRs) are the largest class of cell surface receptors in the
genome and the most successful family of targets of FDA-approved drugs. New frontiers in …

It is estimated that nearly a third of people who abuse drugs started with prescription opioid
medicines. Approximately, 11.5 million Americans used prescription drugs recreationally in …

Classical opioid analgesics, including morphine, mediate all of their desired and undesired
effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for …

G protein-coupled receptors (GPCRs) remain a major domain of pharmaceutical discovery.
The identification of GPCR lead compounds and their optimization are now structure-based …

Opioids continue to be of use for the treatment of pain. Most clinically used analgesics target
the μ opioid receptor whose activation results in adverse effects like respiratory depression …

Opioids are among the most effective analgesics available and are the first choice in the
treatment of acute severe pain. However, partial efficacy, a tendency to produce tolerance …

Opioids such as morphine and oxycodone are analgesics frequently prescribed for the
treatment of moderate or severe pain. Unfortunately, these medications are associated with …

Allosteric modulators of G-protein-coupled receptors (GPCRs) enhance signaling by binding
to GPCRs concurrently with their orthosteric ligands, offering a novel approach to overcome …

Opioid receptors are 7‐transmembrane domain receptors that couple to heterotrimeric G
proteins. The endogenous ligands for opioid receptors are peptides which bind to the …

Fear and emotional learning are modulated by endogenous opioids but the cellular basis for
this is unknown. The intercalated cells (ITCs) gate amygdala output and thus regulate the …